TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07224581: Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder

Sponsor: GRIN Therapeutics, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 100 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT07224581 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07224581 Rescue Dossier →